Story
US Transportation Secretary Pushes to Expedite Aircraft Certification Amid China Competition Concerns

Summary
Transportation Secretary Sean Duffy stated the U.S. must speed up its aircraft approval process to maintain a competitive edge against China and encourage private investment in aviation innovation. The move follows existing FAA efforts to modernize certification.
The U.S. must accelerate its process for certifying new aircraft to prevent losing ground to competitors like China, Transportation Secretary Sean Duffy said on Wednesday. He warned that lengthy approval timelines are stifling innovation and deterring private investment in the aerospace sector.
"If we can’t move at a different pace in certification, we’re going to lose. China is going to beat us," Duffy told reporters at an event in Washington, according to Reuters. He argued that the current system, which can take a decade for approvals, discourages the private capital necessary to fund new aviation technologies.
Regulatory Delays and Industry Impact
The current certification process for a new airplane can take five or more years, requiring extensive testing and documentation. These protracted timelines directly affect major aerospace manufacturers and their product pipelines.
Recent examples highlight the delays faced by the industry:
- Boeing's 737 MAX 7 certification took over eight years before it was finally approved in August.
- The certification for the company's larger 777X jet is currently more than five years behind its original schedule.
AdA streamlined process could benefit manufacturers including Boeing, Airbus, Embraer, and Bombardier by allowing them to bring new, more efficient aircraft to market faster.
FAA Modernization Efforts
The push to reform the system aligns with ongoing efforts at the Federal Aviation Administration (FAA). In June, the agency proposed changes aimed at modernizing and speeding up the certification of new commercial planes.
FAA Administrator Bryan Bedford has confirmed the agency is working on several projects with industry partners "to see how they can streamline the process." According to a previous Reuters report, these plans include reducing the number of exemptions and special conditions required during certification, a move intended to create a more efficient regulatory pathway.
Read next
More on Stocks
Jefferies Identifies Three Biotech Firms with Blockbuster Drug Potential
Investment firm Jefferies has highlighted Delphia Therapeutics, Axsome Therapeutics, and BridgeBio Pharma as undervalued biotech companies with strong late-stage pipelines and significant commercial prospects.

Synopsys Shares Rise on OpenAI Partnership and Strong Revenue Forecast
Chip design software leader Synopsys is partnering with OpenAI on a revenue-sharing basis to develop a specialized AI model for semiconductor design, a move that boosted its stock and financial outlook.

Jefferies Initiates Coverage on Molbio Diagnostics with 'Buy' Rating
Jefferies has initiated coverage on Molbio Diagnostics, naming it a top pick in India's medical supplies sector with a 'Buy' rating and a price target of INR 1,600, citing the strength of its point-of-care diagnostics platform.

Peoples Bancorp Stock Drops on $728 Million All-Stock Deal for Capital Bancorp
Shares of Peoples Bancorp fell over 5% after the bank announced it would acquire Capital Bancorp in an all-stock transaction valued at approximately $728.1 million, raising investor concerns about share dilution.